© 2018 LP-DG® Science

Exit.st0{fill:none;stroke:#FFFFFF;stroke-width:2;stroke-linecap:round;stroke-linejoin:round;stroke-miterlimit:10;} .st1{fill:none;stroke:#00d9ff;stroke-width:1;enable-background:new;} .st2{fill:none;stroke:#FFFFFF;stroke-width:1;enable-background:new;}
/front/assets/b0_bg.b9f56.png
/front/assets/b1.4d847.png
/front/assets/b2.06d15.png
/front/assets/b3.e5655.png
/front/assets/b4.6dac4.png
/front/assets/b5.2ecb4.png
/front/assets/b6.feb5a.png
/front/assets/b7.9e3a3.png
/front/assets/b8.f130a.png
/front/assets/b9.660ae.png
/front/assets/b10.47360.png
/front/assets/b11.f3d7e.png
/front/assets/b12.a0e95.png
Lacticaseibacillus paracasei DG enhances the lactoferrin anti-SARS-CoV-2 response in Caco-2 cells
GUT MICROBES 2021, VOL. 13, NO. 1, e1961970 (12 pages)

ABSTRACT
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing the ongoing global pandemic of coronavirus disease 2019 (COVID-19), which primarily manifests with respira-tory distress and may also lead to symptoms associated with the gastrointestinal tract. Probiotics are living microorganisms that have been shown to confer immune benefits. In this study, we investigated the immunomodulatory effects and anti-SARS-CoV-2 activity of three different Lacticaseibacillus probiotic strains, either alone or in combination with lactoferrin, using the intestinal epithelial Caco-2 cell line. Our results revealed that the Lacticaseibacillus paracasei DG strain significantly induced the expression of genes involved in protective antiviral immunity and prevented the expression of proinflammatory genes triggered by SARS-CoV-2 infection. Moreover, L. paracasei DG significantly inhibited SARS-CoV-2 infection in vitro. L. paracasei DG also positively affected the antiviral immune activity of lactoferrin and significantly augmented its anti-SARS-CoV-2 activity in Caco-2 intestinal epithelial cells.
Overall, our work shows that the probiotic strain L. paracasei DG is a promising candidate that exhibits prophylactic potential against SARS-CoV-2
infection.

 

Authors
Claudio Salaris, Melania Scarpa, Marina Elli, Alice Bertolini, Simone Guglielmetti, Fabrizio Pregliasco, Paola Brun, and Ignazio Castagliuolo

Cookie Policy

This website uses technical and profiling cookies collecting data in aggregate form. By closing this banner, scrolling this page or clicking any of its elements you consent to the use of cookies.

Healthcare professionals

Part of the information contained in this website is exclusively addressed to healthcare professionals. Please confirm that you are a healthcare professional. Are you a healthcare professional?

Yes, I am
No, I am not
Content to third part

This website contains links/references to third-party websites. By such links, SOFAR does not provide any guarantee nor gives its approval to their contents and quality. SOFAR does not have and does not accept any responsibility for the contents or the availability of such websites; SOFAR does not accept any liability for damage or injury resulting from the use of such contents, of whatever form. Users access such websites at their own risk. The information contained in this website is for information purposes only and not for diagnostic or therapeutic purposes. Thus, it does not substitute in any way medical and /or expert or other healthcare professionals or specialists ‘advice.

Duly noted